Manoj Indurkar

Manoj Indurkar

Auto-generated profile, based on publicly available information

Manoj Indurkar

Professor, Department of Medicine, Shyam Shah Medical College, Rewa, Madhya Pradesh, India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Enliven: Journal of Genetics, Molecular and Cellular Biology
Verified
Journal Article
Open access
ATArvind Kumar Tripathi
Arvind Kumar Tripathi
SSSmriti Shukla
Smriti Shukla
JTJitendra Kumar Tripathi
Jitendra Kumar Tripathi
RSRishabh Dev Saket
Rishabh Dev Saket
SKSrikant Kol
Srikant Kol
MIManoj Indurkar
Manoj Indurkar
Enliven: Journal of Genetic, Molecular and Cellular Biology is an Open access, peer reviewed international journal and it aims to publish different types of articles on emerging developments and supports current and upcoming research in the field of genetics. This journal also allows articles on molecular biology and cell biology.

22 January 2018 in Journal of Evolution of Medical and Dental Sciences
Verified
Journal Article
Open access
PNPradeep Nigam
Pradeep Nigam
RPRavi Prakash Pandey
Ravi Prakash Pandey
MPMeghna Pawar
Meghna Pawar
MIManoj Indurkar
Manoj Indurkar

3 May 2022 in Asian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
STSaritesh Kumar Thakur
Saritesh Kumar Thakur
PIPallavi Indurkar
Pallavi Indurkar
DMDinesh Kumar Malviya
Dinesh Kumar Malviya
MIManoj Indurkar
Manoj Indurkar
Background: Stroke is the 2nd largest cause of mortality world over. In the intensive care unit (ICU), severity scales are crucial adjuncts of treatment for anticipating patient outcomes, comparing quality of care, and stratification for clinical studies. They are an important aspect of making better health-care judgments and identifying people with unusual outcomes. This study was conducted to assess and compare Acute Physiology and Chronic Health Evaluation II (APACHE II) score and National Institutes of Health Stroke Scale (NIHSS) score as predictors of mortality in cerebrovascular accident (CVA) patients admitted in medical intensive care unit (ICU) of tertiary care center, Rewa. Aims and Objectives: To evaluate APACHE II score, NIHSS score and APACHE II + NIHSS score as a predictor of short term mortality in CVA patients. Materials and Methods: This was a cross-sectional, analytical study conducted in the Department of Medicine, Sanjay Gandhi Memorial Hospital, associated with Shyam Shah Medical College, Rewa (M.P), between January 2020 and June 2021. The APACHE II score, NIHSS score, and APACHE II+NIHSS scores were calculated for each patient on day of admission and patients were followed up for a maximum period of 7 days. The area under receiver operating characteristic (ROC) curve was used to measure the ability of these scoring systems to forecast the prognosis, to find the best dividing value. Results: Out of 154 patients of CVA, 102 were male and 52 were female. In both sexes, the highest frequency of CVA was seen in those over 55 years of age. The mean age of the participants in the study was 62.70±12.62 years while it was 61.98±12.83 years for males and 64.13±12.19 years for females. The mean APACHE II score in death group was 29.45±10.095, mean NIHSS score in death group was 32.45±6.486, and the mean of both scores combined in death group was 61.91±14.017 and the mean of APACHE II score in survival group was 12.92±6.478, mean NIHSS score in survival group was 14.09±8.099, and the mean of both scores combined in survival group was 27.76±14.090. The APACHE II score had an area under the curve (AUC) of 0.919 which is slightly more than the NIHSS score which had the AUC of 0.913 and the sum of the two scores had the highest area under the ROC curve which is 0.947. According to Youden’s index, the dividing value for the APACHE II score is 21, the NIHSS score is 22, and APACHE II+NIHSS score was 42. Conclusions: Application of APACHE II and NIHSS scores provides an objective method to decide prognosis and plan management of CVA patients. It also helps in deciding whether the patient needs to manage in neurology ward or ICU depending on the dividing value. Both the scores have good ability to predict the short-term prognosis of CVA patients and the combination of these two can provide an even better measure of mortality.

1 February 2025 in Asian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
CSChetan Solanki
Chetan Solanki
KSKuwer Devi Singh
Kuwer Devi Singh
STSunil Kumar Tripathi
Sunil Kumar Tripathi
MIManoj Indurkar
Manoj Indurkar
RTRakesh Kumar Tikadar
Rakesh Kumar Tikadar
Background: Thrombolytic therapy has emerged as one of the most effective interventions for acute myocardial infarction, a condition that is the leading cause of mortality worldwide. Aims and Objectives: This study aimed to evaluate the efficacy and clinical outcomes of Streptokinase (SK) in young patients with ST-elevation myocardial infarction (STEMI) based on coronary angiography performed 12–24 h post-thrombolysis. Materials and Methods: This observational, cross-sectional study included 50 patients diagnosed with STEMI of age between 18 and 40 years and treated with SK between September 2022 and August 2023 in India. The efficacy of SK was assessed through coronary angiography performed 12–24 h post-thrombolysis and ST-segment resolution on electrocardiogram. Clinical outcomes, including adverse events and mortality, were recorded. Results: The majority of patients (66%) were 31–40 years old, with males constituting 88% of the population. Single vessel disease was predominant (84%) among the study population. Anterior wall myocardial infarction emerged as the predominant type of infarction, accounting for 56% of patients in the present study. Successful thrombolysis was achieved in 67.85% of patients treated within 3 h of symptom onset. Adverse events occurred in 52% of patients, with left ventricular failure being the most frequent complication (36%), followed by arrhythmia (26%). The study observed a relatively low mortality rate of 8% among young patients with STEMI. Conclusion: Coronary angiography findings demonstrate that SK is effective in treating young patients with STEMI, particularly when administered within 3 h of symptom onset. Despite frequent adverse events, mortality rates remained low.

31 May 2021 in Journal of Evidence Based Medicine and Healthcare
Verified
Journal Article
Closed access
NMNeera Marathe
Neera Marathe
AAAashutosh Asati
Aashutosh Asati
Alok Pratap SinghAlok Pratap Singh
Alok Pratap Singh
MIManoj Indurkar
Manoj Indurkar
STSaritesh Kuma Thakur
Saritesh Kuma Thakur
BACKGROUND The clinical spectrum of SARS–CoV-2 infection encompasses asymptomatic infection, mild upper respiratory tract infection, and severe viral pneumonia with respiratory failure and even death. This study attempts to estimate the time interval between symptoms onset to severity, time taken for hospitalization, length of stay in hospital along with demographic and clinical characteristics of deceased patients infected with Covid-19. METHODS This retrospective study was conducted in SSMC associated Dedicated Covid Hospital, Rewa district, India. Covid-19 positive deaths (112) that occurred from May 2020 to January 2021 in this institute were considered for this study. Information regarding socio-demographic profile, systemic diseases / underlying medical conditions, signs and symptoms of the disease, clinical course, and investigations were collected and analysed. Time duration variables included were time from the initial symptom to breathlessness, time taken to seek treatment, delay in hospitalization, and length of stay in the hospital. RESULTS Elderly males with 2 or more comorbid conditions were found to be at higher risk of mortality. Median duration from onset of initial symptom to treatment seeking / hospitalization in DCH was 5 days. While mean duration from onset of initial symptoms to onset of breathlessness was 2 days 6 hrs. There was a delay of 3 days in hospitalization after experiencing breathlessness. 90 % patients had bilateral lung involvement at the time of admission. More than half of the patients had multiple organ involvement. Positive correlation was observed in delay in hospitalization, with syndrome severity at the time of admission and negative correlation with length of stay in hospital. CONCLUSIONS Delay in hospitalization is observed as an important factor which affects clinical course. Disease severity increases and length of stay decreases with delayed presentation at the time of admission. It should be addressed with awareness generation activities in community and self-assessment tool appropriate and suitable for implementing in general population. KEYWORDS Covid 19, Covid Infection, Mortality, Time Delay, Length of Stay (LoS)

3 May 2022 in Asian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
PIPallavi Indurkar
Pallavi Indurkar
AAAashutosh Asati
Aashutosh Asati
YSYasmeen Siddiqui
Yasmeen Siddiqui
SNShubhangi Nayak
Shubhangi Nayak
MIManoj Indurkar
Manoj Indurkar
Background: Second wave of coronavirus disease 2019 (Covid-19) pandemic has been particularly devastating in India. COVID-19 and mucormycosis (also known as black fungus) are causing comorbid conditions to worsen the extent of infection and mortality rates especially in India. Mucormycosis can involve nose, sinuses, orbit, central nervous system, lung (pulmonary), gastrointestinal tract any many other organs, but rhino orbital cerebral mucormycosis is the most common variety seen. Rapidity of dissemination of mucormycosis is an extraordinary phenomenon and a delay in the diagnosis could be fatal. Aims and Objectives: The objective of this study is to document the clinical features, radiological extent, risk factors, management,and outcome of mucormycosis. Materials and Methods: The study was retrospective observational study. Eighty-two mucormycosis patients admitted in SGMH Rewa were selected as study subjects. Data regarding clinical features, radiological extent, associated risk factors, comorbidities, management during hospital stay, and outcome of mucormycosis patients were collected on excel sheet and analyzed using appropriate statistical tests. Results: In our study, majority of the patients were unvaccinated (88%). Most common presenting complaint was nasal congestion with or without discharge in 78% patients followed by Facial swelling, visual disturbances, facial weakness, dental pain, etc. On CT or magnetic resonance imaging examination, all cases of mucormycosis had maxillary sinus (100%) involvement, followed by ethmoid (82%) and sphenoid (78%) sinuses. Diabetes mellitus was most common comorbidity seen in 52% cases. About 83% cases had history of receiving high dose steroid intravenously during management of COVID illness. Among study cases 72% patients have taken oxygen supplementation for more than 72 h, for COVID-19 pneumonia before hospitalization for mucormycosis. Therapy of Liposomal Amphotericin B and Oral Triazole (predominantly oral Posaconazole) was the most common medical treatment offered to all patients with COVID associated mucorpatient. Functional endoscopic sinus surgery was done on 93% cases followed by Modified Denker’s procedure was done in 12% cases. Conclusion: In our study, mucormycosis appears to be associated with COVID-19, diabetes, and use of corticosteroids. Full vaccination with COVID-19 vaccines, judicious use of corticosteroids in patients with COVID-19 and strict control of blood glucose level along with timely and proper management is highly recommended to reduce the incidence of fatal mucormycosis.